Compare Adaptive Biotechnologies Corp (ADPT) vs Taskus Inc (TASK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Taskus Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.93 (market cap $3.33B), while Taskus Inc trades at $5.08 (market cap $475.98M). The key difference: Adaptive Biotechnologies Corp is far larger — about 7× Taskus Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | TASK | |
|---|---|---|
Market Cap | $3.33B | $475.98M |
Sector | Health | Technology |
52-Week High | $22.37 | $18.21 |
52-Week Low | $10.24 | $4.57 |
Enterprise Value | $3.19B | $871.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
TaskUs trades at $5.19, up 3.18% today, with a bearish technical signal despite strong fundamentals including a P/E of 4.59 and net income margin of 8.7%. Recent Q1 2026 earnings missed expectations, but revenue reached $1.18B in 2025. The company appointed a new CFO in June 2026 and reported growing interest in robotaxi services, indicating strategic positioning in digital customer experience.
The stock appears undervalued with a consensus price target of $9.50, offering significant upside potential. Risks include recent earnings volatility and competitive pressures in outsourcing services. Analyst sentiment is mixed with 55% buy ratings, suggesting cautious optimism amid near-term execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
